title: Increased levels of soluble tumour necrosis factor receptor-I (P55) and decreased IgG1 reactivities in HIV-1 patients with cytomegalovirus disease.
abstract: The purpose of the study was to investigate potential associations between tumour necrosis factor (TNF), soluble TNF receptors (sTNF-Rs), immunoglobulin (Ig)G subclasses and development of cytomegalovirus (CMV) disease amongst human immunodeficiency virus (HIV)-1 patients. We enrolled HIV-1 patients with CD4 counts less than 100/microl in a prospective study and followed them over 1 year for development of CMV disease. Concentrations of TNF, sTNF-RI, sTNF-RII and IgG subclass reactivities were measured by ELISA; levels of CMV pp65 antigenaemia were determined as numbers of pp65 expressing cells/100,000 cells and were measured by staining of leucocytes; and HIV-1 RNA loads were measured by polymerase chain reaction (PCR). Eighteen patients studied with CMV disease had higher levels of sTNF-RI than 18 similar patients without CMV disease. Concentrations of sTNF-RI correlated with levels of CMV antigenaemia in blood samples collected before the development of CMV disease. Patients with CMV disease had lower levels of IgG1 reactivities to CMV than patients without CMV disease. We conclude that increased levels of sTNF-RI and decreased IgG1 reactivities are associated with an increased risk of development of CMV disease among HIV-1 patients.
authors.affiliation: Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
authors.forename: P H
authors.initials: PH
authors.lastname: Jakobsen
authors.forename: K K
authors.initials: KK
authors.lastname: Dodt
authors.forename: C N
authors.initials: CN
authors.lastname: Meyer
authors.forename: T
authors.initials: T
authors.lastname: Katzenstein
authors.forename: J
authors.initials: J
authors.lastname: Gerstoft
authors.forename: P
authors.initials: P
authors.lastname: Skinhøj
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000276:immunology*; D000328:Adult; D000914:Antibodies, Viral / Q000145:classification / Q000276:immunology*; D015703:Antigens, CD / Q000097:blood*; D000956:Antigens, Viral / Q000097:blood / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000097:blood / Q000150:complications / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D007074:Immunoglobulin G / Q000145:classification / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D012995:Solubility; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D019562:Viral Load
chemical_list: D000914:Antibodies, Viral; D015703:Antigens, CD; D000956:Antigens, Viral; D007074:Immunoglobulin G; D012367:RNA, Viral; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha